| General Information of Drug Metabolite (DM) (ID: DM005020) |
| DM Name |
Cabotegravir M3
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronosyltransferase 1A1 (UGT1A1)
|
DME0004
|
| Multi-steps Reaction - Oxidationn defluorination; glutathione conjugation |
GSK-1265744
|
[1] , [2] |
|
UDP-glucuronosyltransferase 1A9 (UGT1A9)
|
DME0042
|
| Multi-steps Reaction - Oxidationn defluorination; glutathione conjugation |
GSK-1265744
|
[1] , [2] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| GSK-1265744 |
DR1829
|
Phase 2 |
Human immunodeficiency virus infection |
|
|
| References |
| 1 |
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
|
| 2 |
Correction to "Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans"
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
